|
| |
Horizon Discovery Signs Technology
Evaluation Agreement with Array BioPharma
Cambridge, UK, October 27th 2009 – Horizon Discovery (Horizon) today
announced it has signed a non-exclusive commercial agreement with Array
BioPharma Inc. (Array) to evaluate a novel target for its activity and
selectivity on a specific cancer pathway using its X-MAN technology.
X-MAN ‘Mutant And Normal’ human isogenic cell-lines are the first
genetically-defined in vitro models of human cancer and non-cancerous cell-types
that are being widely adopted to accelerate the discovery of novel
‘personalised’ medicines and their optimal assessment in clinical trials.
Under the agreement, Array will evaluate a panel of X-MAN cell lines, each
carrying a specific mutant cancer gene and their matched normal parental genetic
backgrounds. These lines are intended to assist Array in gathering information
relating to the potential utility of their compounds. Array will share certain
data during the course of the evaluation period which will begin in October
2009.
Dr. Darrin M Disley, Commercial Director and Chairman of Horizon says, “We are
rapidly getting our novel ‘patient-relevant’ X-MAN cancer models into real world
drug discovery research programs and are excited to be working with a
forward-thinking company like Array. The evaluation program is expandable and
will generate additional data on the ability of X-MAN cell lines to find novel
‘personalised’ cancer therapies.”
About Horizon Discovery
Horizon Discovery is a translational genomics company founded in June 2007 and
is headquartered at the Babraham Research Campus, Cambridge, UK and with
additional research laboratories in Torino, Italy. Horizon’s goal is to convert
new information on the genetic causes of cancer into laboratory models that will
facilitate the discovery of drugs that target these defects. Central to this aim
is Horizon Discovery’s offering of isogenic cell-lines, which represent accurate
models of defined cancer patient populations and their matched normal genetic
backgrounds – a missing link in the rational and efficient development of novel
targeted anti-cancer agents.
Contact: Dr Darrin M Disley on +44 (0)1223 303049 or +44 (0)7786 133893
www.horizondiscovery.com
| |
|
